Private Equity

Private equity has seen a huge growth opportunity in the ASC industry and the specialties the facilities offer, including gastroenterology and ophthalmology. 

Private equity in 2022 closed on almost $90 billion in healthcare deals, according to an April 10 report from consulting firm Bain & Co.

As private equity increasingly invests in the ASC industry, many leaders are wondering how it will affect practice growth.

Here are five private equity updates since Feb. 22:

Here are five key things to know about private equity and ASCs:

Private equity's interest in ASCs and physicians over the last decade has helped spur a migration of procedures to the outpatient setting, and cardiology could be the next target. 

Although the supply of orthopedic surgeons in the U.S. is low, the specialty remains attractive for private equity investors, according to a report in the Journal of Orthopaedic Experience & Innovation.

Here are five updates and studies on private equity since Feb. 1:

The value of healthcare private equity deals in 2021 was 378 percent higher than that of 2012.

Private equity firm Shore Capital Partners has made 23 healthcare service platform deals since 2020, according to data company PitchBook's "Healthcare Services Report" for the fourth quarter of 2022.